Context Therapeutics (CNTX) Price & Analysis

Compare

184 Followers

CNTX Stock Chart & Stats

$1.12

$0.09(8.26%)

At close: Jan 08 4:00 PM EST

$1.12

$0.09(8.26%)

Day’s Range― - ―

52-Week Range$0.49 - $1.65

Previous CloseN/A

Volume293.07K

Average Volume (3M)386.54K

Market Cap

$102.90M

Enterprise Value$15.42M

Total Cash (Recent Filing)$76.94M

Total Debt (Recent Filing)$140.20K

Price to Earnings (P/E)―

Beta1.03

Next Earnings

Mar 25, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding91,879,170

10 Day Avg. Volume401,596

30 Day Avg. Volume386,536

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.64

Price to Sales (P/S)0.00

P/FCF Ratio-2.09

Enterprise Value/Market Cap0.15

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.79K

Enterprise Value/Ebitda-0.53

Forecast

1Y Price Target

$4.75

Price Target Upside324.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsThe company is executing on its clinic programs around the bispecific portfolio and positioning for key data readouts in 2026.

Market PerformanceCNTX shares have risen approximately 150% since early June, indicating positive sentiment and recovery in the biotech market.

Safety And EfficacyThe safety profile of CTIM-76 appears benign with no CRS greater than Grade 1 noted and no dose-limiting toxicities observed, indicating a good safety margin.

Bears Say

Context Therapeutics News

Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting

Context Therapeutics (CNTX) shared two posters discussing the Company’s CT-95 and CT-202 programs at the Society for Immunotherapy...

24d ago

CNTX

Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Context Therapeutics (CNTX) to $5 from $4 and keeps a...

25d ago

CNTX

Context Therapeutics reports Q3 EPS (10c), consensus (9c)

“We believe the early clinical data for CTIM-76 provides encouraging early signs of antitumor activity for Context’s T...

26d ago

CNTX

Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on Context Therapeutics. The associated price target...

24d ago

CNTX

Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on CNTX stock, giving a Buy rating on...

25d ago

CNTX

Context Therapeutics Reports Improved Quarterly Results

Context Therapeutics, Inc. ( ($CNTX) ) has released its Q3 earnings. Here is a breakdown of the information...

26d ago

CNTX

Context Therapeutics Reports Q3 2025 Financial Results

The latest update is out from Context Therapeutics ( ($CNTX) ). On November 5, 2025, Context Therapeutics announced...

26d ago

CNTX

Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study

Context Therapeutics, Inc. (($CNTX)) announced an update on their ongoing clinical study. Context Therapeutics, Inc. is conducting a...

1M ago

CNTX

Context Therapeutics’ CT-95 Study: A Potential Game-Changer in Cancer Treatment

Context Therapeutics, Inc. (($CNTX)) announced an update on their ongoing clinical study. Context Therapeutics, Inc. is conducting a...

1M ago

CNTX

Context Therapeutics Amends Sales Agreement with Leerink

An announcement from Context Therapeutics ( ($CNTX) ) is now available. Context Therapeutics Inc. has amended its Sales...

1M ago

CNTX

Context Therapeutics Regains Nasdaq Compliance

The latest update is out from Context Therapeutics ( ($CNTX) ). Context Therapeutics Inc. received a notification from...

1M ago

CNTX

Context Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Context Therapeutics (CNTX) with an Overweight rating. Context is an under-the-radar oncology company...

2M ago

CNTX

Context Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Context Therapeutics (CNTX) with an Overweight rating. Published first on TheFly – the...

2M ago

CNTX

Context Therapeutics management to meet with Maxim

Meeting to be held on September 29-October 1 hosted by Maxim. Published first on TheFly – the ultimate...

2M ago

CNTX

CNTX FAQ

What was Context Therapeutics’s price range in the past 12 months?

Context Therapeutics lowest stock price was $0.49 and its highest was $1.65 in the past 12 months.

What is Context Therapeutics’s market cap?

Context Therapeutics’s market cap is $102.90M.

When is Context Therapeutics’s upcoming earnings report date?

Context Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 114 days.

How were Context Therapeutics’s earnings last quarter?

Context Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.012.

Is Context Therapeutics overvalued?

According to Wall Street analysts Context Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Context Therapeutics pay dividends?

Context Therapeutics does not currently pay dividends.

What is Context Therapeutics’s EPS estimate?

Context Therapeutics’s EPS estimate is -0.1.

How many shares outstanding does Context Therapeutics have?

Context Therapeutics has 91,879,170 shares outstanding.

What happened to Context Therapeutics’s price movement after its last earnings report?

Context Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went down -5.31%.

Which hedge fund is a major shareholder of Context Therapeutics?

Currently, no hedge funds are holding shares in CNTX

Context Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-33.68%

Trailing 12-Months

Asset Growth

-8.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Context Therapeutics

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics (CNTX) Earnings & Revenues

Historic Earnings Reports

CNTX Stock 12 Month Forecast

Average Price Target

$4.75

▲(324.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.09,1.390769230769231,1.6915384615384617,1.9923076923076923,2.2930769230769235,2.5938461538461537,2.894615384615385,3.195384615384616,3.496153846153846,3.7969230769230773,4.0976923076923075,4.398461538461539,4.69923076923077,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.09,1.3715384615384616,1.6530769230769233,1.9346153846153848,2.2161538461538464,2.497692307692308,2.77923076923077,3.060769230769231,3.342307692307693,3.623846153846154,3.905384615384616,4.186923076923077,4.468461538461539,{"y":4.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.09,1.3138461538461539,1.537692307692308,1.7615384615384617,1.9853846153846155,2.2092307692307696,2.433076923076923,2.656923076923077,2.880769230769231,3.1046153846153848,3.3284615384615384,3.552307692307693,3.7761538461538464,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.23,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >